Podchaser Logo
Home
SCCM Pod-504 CCM: Baricitinib or Tocilizumab for Severe COVID-19

SCCM Pod-504 CCM: Baricitinib or Tocilizumab for Severe COVID-19

Released Monday, 25th March 2024
Good episode? Give it some love!
SCCM Pod-504 CCM: Baricitinib or Tocilizumab for Severe COVID-19

SCCM Pod-504 CCM: Baricitinib or Tocilizumab for Severe COVID-19

SCCM Pod-504 CCM: Baricitinib or Tocilizumab for Severe COVID-19

SCCM Pod-504 CCM: Baricitinib or Tocilizumab for Severe COVID-19

Monday, 25th March 2024
Good episode? Give it some love!
Rate Episode

Host Marilyn N. Bulloch, PharmD, BCPS, FCCM, is joined by Joy Peterson, PharmD, BCPS, BCIDP, Neha Paranjape, MD, MPH, to discuss the article, "Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19," (Crit Care Med. March 2023 51(3):337-346) which delves into the comparative outcomes, mortality rates, and adverse effects of baricitinib and tocilizumab in severe COVID-19 cases. Dr. Peterson is a Clinical Pharmacy Specialist in infectious disease, and Dr. Paranjape is an Infectious Disease Specialist at Wellstar Health System in Marietta, Georgia.

Show More

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features